skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical relevance of maximal inspiratory pressure: determination in COPD exacerbation

Original Research

(2410) Views  (775) Full article downloads

Authors: Voicu Tudorache, Cristian Oancea, Ovidiu Fira Mlădinescu

Published Date April 2010 Volume 2010:5 Pages 119 - 123
DOI: http://dx.doi.org/10.2147/COPD.S9194

Voicu Tudorache1, Cristian Oancea1, Ovidiu Fira Mlădinescu2

1Department of Pneumology, 2Department of Pathophysiology, Victor Babeş University of Medicine and Pharmacy, Timişoara, Romania

Abstract: Muscle dysfunction represents a pathophysiological feature of chronic obstructive pulmonary disease (COPD). Muscle impairment contributes to decreased effort capacity in these patients at least in the same proportion as pulmonary function limitation. Maximal inspiratory pressure (MIP) is a reliable, noninvasive parameter for assessing the respiratory muscle capacity. The aim of the present study was to determine the role of MIP in effort capacity decrease in COPD patients. MIP was measured in 121 COPD patients without hyperinflation (RV < 150%) together with the following investigations: body plethysmography, body impedance analysis, dynamometry, 6-minute walking test (6MWT), determination of SaO2 and serum levels of highly sensitive C-reactive protein (hsCRP). MIP (kPa) was significantly decreased in moderate-severe stages (6.19 ± 2.42, COPD II; 5.35 ± 2.49, COPD III; 4.56 ± 1.98, COPD IV vs 7.90 ± 2.61 in controls, P < 0.001), whereas the muscle force assessed by dynamometry was decreased only in advanced stages of disease (0.47 ± 0.12, COPD III; 0.41 ± 0.07, COPD IV vs 0.71 ± 0.16 in controls, P < 0.001). The values of MIP correlated (r = 0.53, P = 0.0003) with the distance walked in 6MWT. MIP may provide additive information concerning the general profile of muscle dysfunction in COPD patients.

Keywords: COPD, MIP, exacerbation








Readers of this article also read:

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
Impact of bronchodilator therapy on exercise tolerance in COPD
Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population
Modified BODE indexes: Agreement between multidimensional prognostic systems based on oxygen uptake
Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies
An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects
Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
  • Journal Indexing

    See where all the Dove Press journals are indexed

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio